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Objective: The Austrian Azacitidine Registry is a multi-center database (ClinicalTrials.gov: NCT01595295). The nature
and intent of the registry was to gain a comprehensive view of the use, safety and efficacy of the drug in a broad
range of AML-patients treated in real-life scenarios.
Patients and methods: The sole inclusion criteria were the diagnosis of WHO-AML and treatment with at least
one dose of azacitidine. No formal exclusion criteria existed. A total of 155 AML-patients who were mostly unfit/
ineligible for intensive chemotherapy, or had progressed despite conventional treatment, were included. True
ITT-analyses and exploratory analyses regarding the potential prognostic value of baseline-variables/performance-/
comorbidity-/risk-scores on overall survival (OS), were performed.
Results: In this cohort of 155 pretreated (60%), and/or comorbid (87%), elderly (45% ≥75 years) AML-patients,
azacitidine was well tolerated and efficacious, with an overall response rate (CR, mCR, PR, HI) of 45% in the total
cohort (ITT) and 65% in patients evaluable according to IWG-criteria, respectively. Pre-treatment with conventional
chemotherapy (P = .113), age ≤/>80 years (P = .853), number of comorbidities (P = .476), and bone marrow (BM)
blast count (P = .663) did not influence OS. In multivariate analysis hematologic improvement alone (without the
requirement of concomitant bone marrow blast reduction), although currently not regarded as a standard form of
response assessment in AML, was sufficient to confer OS benefit (18.9 vs. 6.0 months; P = .0015). Further deepening
of response after first response was associated with improved OS (24.7 vs. 13.7 months; P < .001).
Conclusions: In this large cohort of AML-patients treated with azacitidine, age >80 years, number of comorbidities
and/or BM-blasts >30% did not adversely impact OS.
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Acute myeloid leukemia (AML) is an aggressive disease
with an unfavorable prognosis [1,2]. Only approximately
1/3 of elderly AML-patients are eligible for intensive
chemotherapeutic approaches. Results remain poor and
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reproduction in any medium, provided the orcriteria for such treatment (induction mortality of up to
29%; 2 year OS 6-11%) [3-5]. Patients not suitable for in-
tensive chemotherapy due to high age, comorbidities,
poor performance status and/or adverse cytogenetics, or
who have failed these treatment options, are frequently
offered best supportive care (BSC) only [6], and the
prognosis is dismal [7]. Other treatment options such as
low-dose cytarabine, topotecan, gemtuzumab ozogamicin,
clofarabine, cloretazine, or tipifarnib have not been promis-
ing [8-14]. Treatment options for AML-patients with >30%
BM-blasts unfit/ineligible for intensive chemotherapeutic
approaches are particularly limited, as hypomethylatingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics
Median age, years (range) 73 (33–91)
WHO diagnosis*, n (%)
t-AML 16 (10.3)
AML-RCA 16 (10.3)
AML-MRF only 88 (56.8)
AML-MRC 13 (8.4)
Preexisting MDS/MPN or MLD 58 (37.4)
Preexisting MDS/MPN or MLD + MRC 17 (11.0)
AML-NOS 35 (22.6)
Peripheral blood blasts, n (%)
0% 58 (37.4)
> 0% 97 (62.6)
Mean,% 14
Median (range),% 3 (0–90)
Bone marrow blasts, n (%)
<20%† 26 (16.8)
20–30% 31 (20.0)
>30% (off label use) 98 (63.2)
Mean,% 42
Median (range),% 35 (0–98)
White blood cell count, n (%)
Non-MP-AML (< 10 G/l) 122 (78.7)
MP-AML (> 10 G/l) 33 (21.3)
Transfusion dependence (TD), n (%)
Any type of TD 101 (65.2)
RBC-TD 97 (62.6)
PLT-TD 60 (38.7)
RBC-TD + PLT-TD 56 (36.1)
IPSS cytogenetic risk‡, n (%)




MRC cytogenetic risk‡, n (%)





Thromboembolic episodes 21 (13.5)
Renal insufficiency 29 (18.7)
Liver disease 20 (12.9)
Diabetes mellitus 26 (16.8)
Coronary artery disease 34 (21.9)
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recently has decitabine been granted EMA-, but not FDA-
approval for the treatment of WHO-AML patients aged




Azacitidine (Vidaza®) received FDA-approval for MDS
and AML with 20-30% BM-blasts in 2004 based on the
results of several CALGB-trials [15]. EMA-approval for
HR-MDS and AML with 20-30% BM-blasts was granted
in 2008 following the pivotal AZA-001 trial [16]. In a
subset-analysis, azacitidine was shown to prolong OS in
elderly AML-patients with 20-30% BM-blasts [17].
The Austrian Azacitidine Registry (AAR) (ClinicalTrials.
gov: NCT01595295) comprises 155 AML-patients who
did not qualify for intensive chemotherapeutic approaches
in most cases, and is currently the largest cohort of AML-
patients treated with azacitidine published to date, with
the highest per capita coverage of AML-patients in a na-
tionwide registry, suggesting limited selection (Additional
file 1: Tables S1 and S2). The aim was to include most
AML-patients treated with azacitidine in Austria, and to
gain a comprehensive view of the use, safety and efficacy
of the drug in a broad range of WHO-defined AML, in-
cluding patients with >30% bone marrow blasts, who have
limited other therapeutic options, and for whom the drug
has not been approved yet.
Results
Patient characteristics
Between 02/2009 and 02/2012, 155 AML-patients from
12 specialized centers for hematology and medical on-
cology were included; No patients were excluded from
the analyses (Additional file 2: Figure S1A). Patient base-
line characteristics can be taken from Table 1. Median
age was 73 (range 33–91); 57% of patients were older
than 75, 23% were older than 80 and 8% were older than
85 years, respectively; 98 patients (63%) had >30% BM-
blasts; 17% had an unfavorable karyotype, and 74% had
an intermediate karyotype according to MRC-criteria
[18]. In the absence of consensus for cytogenetic classifi-
cation of AML in the elderly, we additionally assessed
the IPSS cytogenetic risk categories (Table 1).
Treatment modalities
Azacitidine was administered as first line therapy in 41%
of patients. Bridging to allogeneic stem cell transplant-
ation (allo-SCT), maintenance after complete response
(CR) to chemotherapy, no CR to, or early relapse after
allo-SCT or conventional chemotherapy was the reason
for treatment in 3%, 4%, 3% and 29% of patients, re-
spectively (Table 1). Azacitidine was not always second
line therapy in chemotherapy refractory patients, but
Table 1 Baseline characteristics (Continued)
COPD 15 (9.7)
Prior/concomitant malignancies 35 (22.6)
Number of comorbidities, n (%)
0–1 66 (42.6)
2–3 61 (39.4)
> 3 28 (18.1)
ECOG Prognostic Score, n (%)
ECOG <2 114 (73.6)
ECOG ≥2 41 (26.4)
HCT-CI, n (%)
Low risk 46 (29.7)
Int. risk 46 (29.7)
High risk 50 (32.2)
No data 13 (8.4)
Treatment prior to azacitidine§, n (%)
None 63 (40.6)
Erythropoietin stimulating agents 15 (9.7)
G-CSF 19 (12.3)
Thrombopoietin stimulating agents 1 (0.7)
Iron chelation therapy 5 (3.2)
Thalidomide 3 (1.9)
Lenalidomide 6 (3.9)
Low-dose cytarabine 10 (6.5)
Intensive chemotherapy 60 (38.7)
Others 16 (10.3)
Reason for treatment, n (%)
1st line treatment 63 (40.6)
Bridging to allogeneic SCT# 4 (2.6)
Maintenance after CR to conventional chemotherapy 6 (3.9)
No CR to/early relapse after conventional chemotherapy 45 (29.0)
No CR to/early relapse after allogeneic SCT 5 (3.2)
No CR to other prior treatment 32 (20.6)
t-AML indicates treatment related AML; AML-RCA, AML with recurrent
cytogenetic abnormalities; AML-MRF, AML with MDS related features; MPN,
myeloproliferative neoplasia; MLD, multilineage dysplasia; MRC, MDS-related
cytogenetics; AML-NOS, AML not otherwise specified; MP, myeloproliferative;
COPD, chronic obstructive pulmonary disease; NHL, non-Hodgkin’s lymphoma;
ECOG, Eastern Cooperative Oncology Group; CR, complete response; SCT, stem
cell transplantation;
*If a patient fulfilled criteria for more than one WHO-category, weighting was
performed as follows: t-AML > AML-RCA > AML-MRF.
†BM-blast count was <20%, in those patients with established AML who were
refractory to, -or had no CR after-, conventional chemotherapy or allogeneic
stem cell transplantation.
‡Pre-treatment cytogenetics were available in 92% of patients and were
determined by conventional metaphase karyotyping (46%), interphase-FISH
(16%), or both (38%).
§Numbers may add up to >100% as multiple selections were possible.
#None of the patients for whom azacitidine was intended as bridging was in
complete remission to prior therapies, and all patients had relapsed after multiple
lines of intensive chemotherapy; only one of these patients proceeded to
allogeneic SCT (the others died whilst still on, or within 8 weeks after termination of
azacitidine treatment due to disease progression and/or infectious complications).
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proportion of our patients (28%).
Azacitidine dose, application route, and administration
schedule were exclusively based on the risk/benefit-esti-
mation of the treating physician. The median and mean
number, as well as range of azacitidine courses was 4,
6.3 and 1–24, respectively. Most cycles (90%) were ap-
plied subcutaneously (average dose/cycle 814 mg); 10%
were given intravenously (average dose/cycle 870 mg);
79% of patients predominantly received 7 days of
azacitidine (57% FDA-approved d1-7 (median dose/
cycle 924 mg), 22% 5-2-2 (median dose/cycle 900 mg))
(Additional file 1: Table S3). FDA-approved azacitidine
target-dose (75 mg/m2×7 +/−10%) was reached in 53%
of applied cycles; 214/958 (22%) of all cycles were ad-
ministered as ‘flat’ dosage (i.e. 100 mg azacitidine/cycle-
day; median dose/cycle 700 mg). Dose reduction of
azacitidine due to an adverse event (AE) was necessary
in 28 (18%) patients.Concomitant treatment and best supportive care
measures
In all 958 azacitidine cycles applied to AML-patients,
erythropoietin stimulating agents (ESA) (3%), iron chela-
tion treatment (ICT) (3%), and G-CSF (21%) were given
in parallel to azacitidine when deemed necessary by the
treating physician. ESA and ICT were rarely required
after cycle 5, whereas G-CSF-usage did not show the
same decline.Response
Overall response, defined as complete response (CR),
marrow response (mCR), partial response (PR) and
hematologic improvement (HI), was documented in
45.2% of the total intention-to-treat (ITT) cohort and in
65.4% of patients evaluable according to IWG-criteria [19]
(i.e. had received >2 cycles of azacitidine); Hematologic
improvement was documented in 32% (ITT) and 46%
(IWG), respectively; Best marrow response [20] is shown
in Table 2.
Taking a closer look at responding patients (n = 70),
77% received 7 days of azacitidine in the first cycle (65%
d1-7, 13% 5-2-2) and 82% predominantly received 7 days
of azacitidine over all cycles (52% d1-7 (median dose/
cycle 871 mg), 30% 5-2-2 (median dose/cycle 837 mg)
(Additional file 1: Table S3). Of note, the distribution of
applied schedules, as well as the median and mean
azacitidine dosages/cycle did not differ between re-
sponders and non-responders (Additional file 1: Table S3).
The median and mean number, as well as range of cycles
received by responding patients is 9, 10.3 and 1–31,
respectively.
Table 2 Response to azacitidine [18,19]
Transfusion independence, n, (% ITT*), [% IWG†]
PLT-TI 24/60 (40.0), 24/43 [55.8]
RBC-TI 35/97 (36.1), 35/69 [50.7]
Hematologic improvement, n, (% ITT), [% IWG‡]
No HI 58 (37.4) [54.2]
HI-Any 49 (31.6) [45.8]
Best marrow response, n (% ITT) [% eval.§]
CR 15 (9.7) [20.0]
mCR 5 (3.2) [6.7]
PR 32 (20.6) [42.7]
mSD 19 (12.3) [25.3]
Primary PD 4 (2.6) [5.3]
Overall response, n, (% ITT), [% IWG‡] 70 (45.2) [65.4]
CR 15 (9.7) [14.0]
mCR 5 (3.2) [4.7]
PR 32 (20.6) [29.9]
mSD with HI 4 (2.6) [3.7]
HI only 14 (9.0) [13.1]
No response 61 (39.4), 37 [34.6]
IWG indicates International Working Group Criteria; TI, transfusion independence; HI, hematologic improvement; mCR, marrow CR; mSD, marrow stable disease;
BMP, bone marrow puncture; PD, progressive disease;
*Concerns all patients that were transfusion dependent at baseline;
†Concerns number of patients that were transfusion dependent at baseline and received >2 cycles of azacitidine and were thus evaluable for response
assessment according to IWG-criteria;
‡Evaluable according to IWG-criteria, i.e. patients that received >2 cycles of azacitidine (n = 107);
§Concerns patients in whom bone marrow puncture was performed (n = 75); bone marrow assessment was performed as clinically necessary, and at the
discretion of the respective treating physician; a total of 140 bone marrow punctures were performed in 75 patients (of patients in whom no bone marrow
puncture was performed, 30 received only one and 18 received only two cycles of azacitidine; of these, 26 died within 2 months and a further 11 died within
6 months after stop of azacitidine treatment).
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Median (mean) time to first response was 4 (3.5)
months. First response occurred after 3, 4 and 5 cycles
in 44%, 77% and 87% of responding patients, respect-
ively, but could be observed as late as cycle 10. First re-
sponse was best response in 46/70 patients (66%).
Further deepening of response after first response was
seen in 24/70 (34%) of responders. Best response was
reached by cycle 8 in 93%, but could be observed as late
as cycle 19. Median (mean) time from first to best re-
sponse was 2.8 (3.6) months, respectively.
Toxicity and adverse events
A total of 501 adverse events were documented in 958
azacitidine cycles. The number of adverse events de-
clined continuously from ~40% of patients in the 1st
cycle to <20% as of cycle ≥10. Overall, 32% of all adverse
events and 20% of grade 3–4 adverse events were attrib-
uted to azacitidine; 22% resulted in hospitalization, 6%
resulted in death; 69% had no consequence for
azacitidine treatment; 6%, 14%, 9%, and 1% resulted indose reduction, treatment pause, termination of treat-
ment, or prolongation of azacitidine cycle duration
>28 days, respectively.
Grade 3–4 neutropenia, thrombocytopenia, and anemia
were documented in 32%, 25%, and 21% of patients,
respectively; clinically relevant bleeding events were noted
in 9% (Table 3). Non-hematologic toxicity was usually mild,
the most common adverse events being fatigue (42%), un-
specified pain (30%), gastro-intestinal (26%), and injection
site reactions (21%). Infectious complications of any grade
were documented in 63%, febrile neutropenia in 18%
(Table 3). Grade 3–4 events occurred in 29% and were
dominated by pulmonary infections, sepsis, and CMV-
reactivations. Hospital admission was required in 43% and
transfer to an intensive care unit was necessary in 4%.
Only 18 non-hematologic grade 3–4 events occurred
in 16 patients (10%): 15/18 of these grade 3–4 events oc-
curred in the cardiac system: left-ventricular output fail-
ure (n = 10), arrhythmia (n = 4), cardiac ischemia (n = 1).
In 10/15 (67%) patients experiencing cardiac grade 3–4
events, pre-existing coronary artery disease, reduced
Table 3 Specific adverse events*,†
Variable Grade n pts., (%) n total events
Hematologic toxicity# G3–4 69 (44.5) 148
Thrombopenia G3–4 38 (24.5) 87
Neutropenia G3–4 49 (31.6) 99
Anemia G3–4 33 (21.3) 80
Bleeding events – 14 (9.0) 31
Febrile neutropenia – 28 (18.1) 46
Infectious complications Total 98 (63.2) 256
G1 14 (9.0) 85
G2 39 (25.2) 107
G3 16 (10.3) 26
G4 29 (18.7) 38
Non-hematologic toxicity
Liver G1-2 1 (0.6) 1
G3-4 0 (0.0) 0
Kidney G1-2 5 (3.2) 5
G3-4 0 (0.0) 0
Heart G1-2 3 (1.9) 5
G3-4 13 (8.4) 15
Blood pressure G1-2 2 (1.3) 2
G3-4 1 (0.6) 1
Metabolic G1-2 1 (0.6) 1
G3-4 0(0.0) 0
Thromboembolic G1-2 9 (5.8) 10
G3-4 1 (0.6) 1
Neurologic G1-2 11 (7.1) 18
G3-4 1 (0.6) 1
Nausea G1-2 16 (10.3) 24
G3-4 0 (0.0) 0
Vomiting G1-2 4 (2.6) 5
G3-4 0 (0.0) 0
Constipation G1-2 3 (1.9) 5
G3-4 0 (0.0) 0
Diarrhea G1-2 17 (11.0) 25
G3-4 0 (0.0) 0
GIT-others G1-2 11 (7.1) 11
G3-4 0 (0.0) 0
Injection site reaction G1-2 32 (20.6) 48
G3-4 0 (0.0) 0
Fatigue Total 65 (41.9) 99
Relieved by rest 24 (15.5) 50
Not relieved by rest 25 (16.1) 32
Limiting self care 16 (10.3) 17
Pain Total 46 (29.7) 78
Mild 25 (16.1) 52
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Table 3 Specific adverse events*,† (Continued)
Moderate 18 (11.6) 23
Severe 3 (1.9) 3
Surgery Total 20 (12.9) 24
Elective 13 (8.4) 16
Emergency 7 (4.5) 8
Fall Total 14 (9.0) 16
With fracture 8 (5.2) 9
With hemorrhage 5 (3.2) 8
Novel solid tumor Yes 3 (1.9) 3
*http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
†National Cancer Institution Toxicity Criteria (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).
#Grade 3–4 cytopenias reported, are those that were documented as adverse events, and thus felt to be a worsening of pre-existing cytopenia by the respective
treating physicians.
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to azacitidine treatment, and worsening was not thought
to be azacitidine-related.Overall survival and potential prognostic parameters
Median OS was 16.3 (95% CI 12.23–19.97) months as of
first diagnosis, and 9.8 (95% CI 8.59–10.93) months as of
treatment start with azacitidine. Median (mean) time from
first diagnosis to treatment start with azacitidine for
untreated (n = 63) versus pretreated (n = 92) patients was
0.6 (4.1) and 8.5 (14.9) months, respectively. Median (mean)
time from initial diagnosis to azacitidine treatment for
patients who received no, one, or multiple lines of conven-
tional chemotherapy prior to azacitidine, was 0.7 (6.7), 1.8
(4.1), and 13.3 (21.7) months, respectively. 48 patients re-
ceived ≤2 cycles of azacitidine; 23 of these died within
1 month of treatment termination, and a further 14 died0.0
Fatigue
grade <3 vs 3
Hematologic toxicity








<2 vs ≥2 
0.2 0.4 0.6
Forest PlotCovariates
Figure 1 Factors significantly influencing overall survival in multivariawithin 6 months. Median (mean) time from azacitidine
treatment stop to death was 1.8 (4.0) months, respectively.
In multivariate analysis the following baseline parameters
had a significant effect on overall survival: peripheral blood
blasts (P = 0.0398) and ECOG performance score (ECOG-
PS) (P = 0.0397) (Figure 1 and Additional file 1: Table S5).
In univariate analysis patients with adverse cytogenetics
(−7q, -7, abn (3q), complex karyotype) (n = 28) had worse
OS than patients with other cytogenetic abnormalities or
normal karyotype (n = 115) (5.1 vs. 10.5 months, P = 0.009)
(Additional file 1: Table S5). Patients pre-treated with
‘imids’ (n = 9), i.e. thalidomide or lenalidomide, may have
worse OS: prior treatment with either of these substances
was associated with a significant adverse effect on survival
(P = 0.008, median OS 3.0 vs. 9.7 months, respectively)
(Additional file 1: Table S5). However, the number of
patients pretreated with thalidomide/lenalidomide was too
small to establish strong conclusions or to perform0.8 1.0 1.2 1.4









Pleyer et al. Journal of Hematology & Oncology 2013, 6:32 Page 7 of 13
http://www.jhoonline.org/content/6/1/32multivariate analysis. Of the 6 patients pretreated with
lenalidomide, 2 had preceeding MDS with -5q as sole aber-
ration, one had a complex karyotype including -5q, one had
a complex karyotype including monosomy 5, one had a
normal karyotype, and in one patient karyotype was not
evaluable.
The absolute number of comorbidities did not adversely
affect OS of AML-patients treated with azacitidine with a
cut-off of <3/≥3 comorbidities (P = 0.151). When a cut-off
of <4/≥4 comorbidities was analyzed, there was trend for
reduced OS, which was however not statistically signifi-
cant (P = 0.086) (Additional file 1: Table S4). MRC-
cytogenetic risk groups could not predict overall survival,
however a trend was noted (P = 0.093).
Baseline factors that did not significantly affect OS in uni-
variate analyses (Additional file 1: Table S4) include WBC
≤/>10G/l (P = 0.346), LDH ≤/>225 IU/l (P = 0.123), S-EPO
level (P = 0.661), RBC-TD (P = 0.542), and PLT-TD
(P = 0.149). Age had no adverse effect on outcome of
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Figure 2 Effect of various factors on overall survival (OS). (a) Effect of
(c) Effect of achievement of any type of hematologic response on OS. (d) E
experiencing a further deepening of response after first response had signi
response was best response.whether a cut-off of </≥75 (P = 0.174) or </≥ 80 years was
chosen (P = 0.853) (Figure 2a). Bone marrow blast count
≤30/>30% had no adverse effect on OS, irrespective of
whether the whole cohort (P = 0.663) was analyzed, or
whether patients with prior intensive CTX (P = 0.313), or
all pretreated patients were excluded (P = 0.127) (Figure 2b,
Additional file 1: Table S4). Prior treatment with ESA (P =
0.873), G-CSF (P = 0.841), low-dose cytarabine (P = 0.630)
or one or several lines of conventional chemotherapy (P =
0.113) had no adverse effect on OS (Additional file 1: Table
S4). In concordance, patients, for whom absence of CR or
refractoriness to prior intensive chemotherapy was the
reason for treatment with azacitidine, did not have worse
OS (P = 0.268).
In multivariate analysis the following response related
factors had a significant effect on overall survival:
hematologic improvement (P = 0.0001) and marrow re-
sponse (P = 0.0005) (Figure 1 and Additional file 1: Table
S5). Any kind of response resulted in significantly longer
OS, be it marrow response (24.7 vs. 15.2 vs. 2.3 monthsAge on OS. (b) Effect of bone marrow blast percentage on OS.
ffect of deepening of response after first response on OS. Patients
ficantly longer overall survival, than those patients for whom first
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8.9 months), RBC-TI (19.3 vs. 9.6 months), or HI in one
or all cell lineages (18.9 vs. 6.0 months) (Figures 1 and 2c,
Additional file 1: Table S5). Continued azacitidine beyond
first response resulted in further deepening of response in
34.3% of responders, which translated into significantly
longer OS (24.7 months), compared with patients for
whom first response was best response (13.7 months)
(P < 0.001) (Figure 2d, Additional file 1: Table S5).
In multivariate analysis the occurrence of fatigue
(P = 0.0299) or hematologic toxicity (P = 0.0447) as ad-
verse events, had an independent prognostic effect on
OS (Figure 1 and Additional file 1: Table S5). Azacitidine
dose or schedule and the occurrence and duration of
various non-hematologic adverse events had no negative
impact on OS (Additional file 1: Table S4).Discussion
With 155 AML-patients included in the AAR and
8.4 million inhabitants, this is the highest per capita cover-
age of AML-patients in a nationwide registry, suggesting
limited selection. The per capita inclusion of AML-patients
into our national registry (18.9 per million inhabitants) is
the largest as compared to data from other countries that
has so far been published (0.06-6.58 per million inhabi-
tants) (Additional file 1: Table S1) [15,17,21-26]. The num-
ber of AML diagnoses per year, as well as the number of
AML-patients included in the respective year for Austria in
general and Salzburg in particular, is presented in
Additional file 1: Table S2 (data obtained from Statistics
Austria, personal communication 14.03.13). The percent-
age of patients in the MRC cytogenetic high-risk category
is 17% in our AML cohort, which seems less than the pro-
portion of cytogenetic high-risk AML-patients reported in
several, but not all previously published smaller AML-
cohorts treated with azacitidine (Additional file 1: Table
S1). Cumulating evidence suggests that patients with
high-risk cytogenetics respond poorly to conventional
chemotherapeutic approaches, and that these patients es-
pecially may be candidates for hypomethylating treatment.
Therefore, according to our understanding, patients with
high-risk cytogenetics should be overrepresented, -rather
than underrepresented-, in underrepresented-, in our
registry, if an explicit selection bias concerning cytogenetic
risk categories were present.
Median age, age range, pretreatment cytogenetic risk
groups, azacitidine schedule and median azacitidine
cycles are comparable to those documented in much
smaller AML-patient-subsets (n = 20-82) in almost all
previously published clinical trials and observational data
so far (Additional file 1: Table S1) Therefore we believe
that selection bias is minimized, both with respect to the
choice of AML-patients for azacitidine treatment, as wellas for the decision to include the patients in the registry
(Additional file 2: Figure S2A).
The most common hematologic and non-hematologic
adverse events, and the rates thereof are almost identical
to previously published data from controlled trials as well
as retrospective analyses [16,27]. CR/mCR-, as well as HI-
rates are comparable to, -and PR-rates slightly higher
than-, the rates obtained in smaller series (n = 20-82)
of AML-patients treated with azacitidine by others
[15,17,21-25]. Due to higher PR-rates, the overall response
rate (Table 2) is one of the highest documented for AML-
patients treated with azacitidine so far.
Median OS of elderly AML-patients is still low,
irrespective of treatment modality. Conventional chemo-
therapy and other treatment options such as low-dose
cytarabine, topotecan, gemtuzumab ozogamicin, clofarabine,
cloretazine, tipifarnib, or laromustine show median OS rates
of 2.0-6.7 months [7-13,28-31]. In comparison, AML-
patients with 20-30% blasts (formerly RAEB-t) treated with
BSC only (n = 223; median age 73a) had a median OS of
5.2 months in a recent update of the Düsseldorf MDS regis-
try data (U.Germing, personal communication, 17/09/2012).
This is similar to 5.0 months OS of AML-patients random-
ized to best supportive care or low-dose cytarabine in a re-
cent phase-III trial of untreated AML [32]. Therapy-naïve
AML-patients (n = 242) randomized to decitabine in the
same trial had a median OS of 7.7 months, which led to a
positive opinion by EMA, with formal approval expected
soon [32]. Previous reports of much smaller series of AML-
patients treated with azacitidine documented median OS
rates of 3, 7–9, 2.5-15, 8, 6–16 and 8.8 months, respectively
[21-25,30]. (The reports giving OS-ranges did not separate
the OS of AML- and MDS-patients explicitly). In light of
the above, our OS results of 9.8 months are encouraging.
Only two subanalysis of randomized clinical trials (CALGB-
9211 (n = 27), AZA-001 (n = 55)) reported longer OS than
observed in our cohort [17,33]. The authors of the latter
stated that this is likely due to exclusion of patients with an
estimated life expectancy <3 months, ECOG-PS >2, t-AML,
prior treatment, or planned allogeneic SCT [16,17]. Overall,
61% of our registry population would have been excluded
from this trial due to these reasons alone; if BM-blast count
>30% is also taken into account, 90% would have been ex-
cluded. We thus consider our OS data to be remarkable,
particularly since they were observed in a real-life AML-
patient cohort, not selected or restricted by stringent inclu-
sion/exclusion-criteria, and in which most patients had no
other treatment option than azacitidine.
Significantly longer OS was observed in patients achiev-
ing any kind of response, be it marrow response, achieve-
ment of RBC/PLT-TI, or HI (Figures 1 and 2c, Additional
file 1: Table S5). Similar results have been shown in
smaller AML-patient cohorts (n = 11) treated with
azacitidine [34]. Others, who did not analyze the HI-rate
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noted, that azacitidine can provide survival benefit, despite
a low CR-rate [17], a finding which is similar to that seen
in high-risk MDS-patients [16]. However, it is for the first
time shown in multivariate analysis, that response in terms
of HI alone, without requirement of concomitant BM-blast
reduction, seems sufficient to confer longer OS in AML-
patients treated with azacitidine (18.9 vs. 6.0 months)
(Figure 1). If the commonly used AML response criteria
[20] were to be applied, patients who experience HI with-
out simultaneous BM-blast reduction would be considered
as having neither CR nor PR, and thus as non-responders,
with the result that treatment with azacitidine would/might
be discontinued. In our opinion these patients should be
considered as responders, and should continue to receive
azacitidine until unambiguous clinical progression (i.e.
renewed transfusion dependence and/or stark reduction of
general performance).
We show for the first time in AML-patients treated with
azacitidine, that further deepening of response after first re-
sponse, i.e. achievement of BM-blast reduction in terms of
PR or (m)CR after HI, seems to translate into significantly
longer OS, compared with patients for whom first response
was best response (Figures 1 and 2d, Additional file 1: Table
S5). Similar results have been shown for MDS-patients
treated with azacitidine [16,35]. Therefore, in analogy to
recommendations for MDS [35,36], these data support the
continued use of azacitidine in responding AML-patients.
It is possible, that a larger percentage of AML-MRF
and t-AML may be present in our registry-population
(Table 1). However, very little recent data is available on
the incidence of all WHO-AML-subgroups in adults in
Europe [37], and the recently published phase-III trial
comparing decitabine vs. conventional care regimen also
had a high percentage (35%) of secondary-AML [30]. In
any case, t-AML is known to be associated with dismal
prognosis [38], and AML-patients with preceding MDS/
MPN and/or MDS-related cytogenetics (MRC) were
shown to have worse OS than AML-NOS [39].
Our registry population includes many elderly and
very old patients: 22% aged 75–79, 15% aged 80–84 and
8% ≥ 85 years, respectively; many of these very old
patients would previously have been treated with best
supportive care only. Importantly, age had no adverse
effect on OS, irrespective of whether a cut-off of </≥75
(Additional file 1: Table S4) or </≥80 years was chosen
(Figure 2a). In addition, only 40% of patients were
untreated prior to azacitidine, whereas 39%, 7% and 6%
were pretreated with conventional chemotherapy, low-dose
cytarabine or ‘imids’, respectively (Table 1). In light of all of
the above, we consider our response and OS results
particularly relevant.
The absolute number of comorbidities had no adverse
effect on OS. Accordingly, the HCT-CI [40], which isbased on the number and weighting of comorbidities,
could not discriminate patient-groups with different OS
(Additional file 1: Table S4), whereas the ECOG-PS [41],
which is based on the patient’s ability to cope with activ-
ities of everyday life, could (Figure 1, Additional file 1:
Table S5). In our opinion, high age and presence of
comorbidities should not lead to a decision to withhold
treatment of azacitidine in favor of BSC, if the patient
has an ECOG-PS < 2.
Azacitidine seems effective in AML, irrespective of
BM-blast count (Additional file 1: Table S4, Figure 2b).
Lack of correlation between survival and median pre-
treatment BM-blast count has previously been reported
in WHO-AML-patients (n = 40) [21]. We believe, that
AML-patients with >30% BM-blasts should not be pre-
cluded from treatment with azacitidine.
Interestingly, patients experiencing hematologic tox-
icity grade 3–4 in any, one, several, or all cell lineages
had significantly better OS (Figure 1). In clinical practice
it is important to note that AML-patients may develop a
worsening of cytopenia(s) during the first two months
prior to azacitidine response, but this does not seem to
be associated with an increased rate of infection or
hemorrhage [14,15]. In fact, even when occurring, these
events did not negatively impact OS in our cohort, and
neither did non-hematologic toxicity, nor duration of ad-
verse events (Additional file 1: Table S4). The majority of
grade 3-4 hematologic adverse events were documented
during early treatment cycles, suggesting that (a) patient
tolerance to azacitidine increases as treatment continues,
(b) a certain amount of aplasia-induction seems necessary
before response occurs, and (c) likely reflects the fact that
most patients respond after cycle 3. Patients in whom
azacitidine dose had to be reduced due to an adverse event
even had improved OS in univariate analyses. This effect
was however lost in multivariate analysis. It seems fair to
state that dose reductions were possible without negative
impact on OS. We deduct that the occurrence of adverse
events should not lead to permanent treatment discon-
tinuation with azacitidine in most cases. Azacitidine
should be continued as planned whenever possible, if ne-
cessary with dose reduction or treatment pause.
Achievement of the FDA-approved target-dose of
75 mg/m2×7 days did not have a significant effect on
OS, and neither did the predominantly applied schedule
(Additional file 1: Table S4). Similar results have been
shown by others for MDS [27,40]. Concerning OS of
responding patients only (n = 70), it made no relevant
difference which regimen or dose was used in the first
cycle, or which regimen or dose was predominantly used
over all cycles (Additional file 1: Table S4). The 5-2-2
regimen and/or dose reductions, be it in days (d1-5)
and/or dose per day (100 mg flat), seem feasible, safe,
and without loss of efficacy. In spite of the impression of
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demonstrated by our data, we still recommend initiation
of azacitidine in the FDA-approved dosage and regimen.
We acknowledge the limitations of data obtained from
a registry and are fully aware, that clinical trials may not
be substituted, but only complemented by these. If
adequate in size and analyzed carefully, registry data can
be of value in supplementing or extending data from
trials. The strength of this manuscript lies in the size of
the documented patient group, that allows statistical
generation of hypothesis, which may be assessed by clin-
ical trials in due time. It was our explicit intention and
the design of the registry not to select patients, but in
contrast to obtain a widespread view of the use, toxicity
and effects of azacitidine in a real-world clinical setting.
We believe this is substantiated by the following facts:
a) The population was substantially pretreated;
b) 48 patients (31%) received only one or two cycles of
azacitidine;
c) 90% of our patient cohort would have been excluded
from the pivotal AZA-001 trial due to reasons listed
in the discussion of the text;
d) azacitidine was used as last resort, or last line
therapy in at least a part of the cohort with a very
low life expectancy; these patients would have
received best supportive care only before azacitidine
was available;
e) 40% of patients were treated with azacitidine 1st line,
as we believed this to be an appropriate option given
their disease characteristics, patient profile and in
the absence of clinically superior alternatives.
We moderately hypothesize and suggest, that our
rather ‘aggressive’ initiation of treatment, irrespective of
comorbidities, bone marrow blast count, age or pre-
treatment, as well as the ‘persistent’ continuation of treat-
ment with azacitidine once the drug was commenced (i.e.
treatment until overt clinical progression, rather than
mere laboratory signs of progression such as stable or
slightly rising blast counts in blood or bone marrow)
might play a part in our results, although this cannot
directly be proven by the data as presented.
Conclusions
In conclusion, azacitidine seems to be well tolerated and
efficacious in WHO-AML-patients in a real-world non-
trial clinical setting. The observed median OS of 9.8 months
in this largely pretreated cohort including 66% of patients
with bone marrow blasts >30% is encouraging. We confirm
the previously reported non-essentiallity of CR for pro-
longation of OS in our cohort of AML-patients treated
with azacitidine. In our opinion, age >80, number of
comorbidities, and/or bone marrow blasts >30% shouldnot preclude patients from treatment with this drug, which
should be continued as long as response is durable, and
onset of overt clinical progression occurs.
Methods
Registry design and patient eligibility
WHO-classified AML [42] and treatment with at least
one dosage of azacitidine were the sole inclusion criteria
(Additional file 2: Figure S2A). No other formal inclu-
sion/exclusion criteria existed. Treatment indication and
the decision to offer treatment with azacitidine, as well
as dosage, dose reductions/escalations, application route,
and administration schedule were exclusively based on
the risk/benefit-estimation of the treating physician.
Registry design and timelines can be taken from
Additional file 3: Figure S2B. Patients receiving azacitidine
prior to EMA-approval, as well as patients with >30% BM-
blasts were informed of off-label use and gave written
informed consent to treatment with azacitidine. Informed
consent to allow the collection of personal data was
obtained for all retrospectively documented patients who
were alive, as well as for all prospectively included patients.
Data collection and monitoring
Data was entered by physicians and/or trained clinical
trial personnel at the respective centers. Central moni-
toring of all data entered in the eCRF including response
evaluations was performed as a quality control measure
by LP, in order to assure data integrity and plausibility
(cut-off date 21.01.2012). Missing data are low and docu-
mented as such. Centers received queries specifying in-
complete data or questions to reconfirm data, if necessary.
Assessment of efficacy, safety and endpoints
Bone marrow punctures/aspirations were performed as
clinically necessary; Marrow response, hematologic im-
provement and overall response were assessed according
to current IWG-criteria [19,20]. Central monitoring of
response in each cycle was performed. A total of 97% of
our cohort had either AML with >30% bone marrow
blasts, was refractory to prior conventional chemother-
apy or had AML with 20-30% bone marrow blasts. The
remaining 3% of patients were refractory to other ther-
apies (e.g. low-dose cytarabine). We therefore are cer-
tain, that the patients included truly suffered from AML,
even without central review of the blast count.
Toxicity and adverse events were assessed according to
the NCI Toxicity Criteria (http://ctep.cancer.gov/protocol
Development/electronic_applications/ctc.htm) and Com-
mon Terminology Criteria for AE (CTCAEv.4) (http://evs.
nci.nih.gov/ftp1/CTCAE/About.html). Grade 3–4 cyto-
penias reported, are those that were documented as adverse
events, and thus felt to be a worsening of pre-existing
cytopenia by the respective treating physicians.
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Overall survival was assessed using the Kaplan-Meier
method. Univariate analyses were performed with log-
rank tests. Cox-regression stratified on the various factors
was used for univariate analyses of risk-factors for OS. For
multivariate analysis Cox-regression with stepwise selec-
tion (entry-level 0.25; level for keeping the variable 0.15)
was used. Univariate analyses were performed and con-
firmed by two independent statisticians [H.A., B.R.]. The
confirmed results were the basis for multivariate analysis.
All variables with P < .05 in univariate analyses were in-
cluded in multivariate analysis, except for those cases,
where parsimony would have been disrupted due to re-
dundancy in the variables. All analyses were performed
with SPSS and SAS. No adjustments were made for mul-
tiple testing.
Additional files
Additional file 1: Table S1. Comparison of overall response rates of all
current full publications on AML patients treated with azacitidine.
Table S2. Number of AML diagnoses per year in Austria, and patient
recruitement to the Austrian Azacitidine Registry (AAR). Table S3.
Azacitidine treatment schedule. Table S4. Factors that did not
significantly affect overall survival. Table S5. Factors significantly
influencing overall survival.
Additional file 2: Figure S1. (CONSORT-Diagram A Describes the
design of, and patient eligibility for the Austrian Azacitidine Registry
(AAR).
Additional file 3: Figure S1. (CONSORT-Diagram B. Describes the
timelines of the Austrian Azacitidine Registry (AAR).
Competing interests
Consultant or advisory role: Lisa Pleyer, Celgene, Bristol-Myers Squibb,
Novartis; Sonja Burgstaller, Celgene; Michael Pfeilstöcker, Celgene, Novartis;
Michael Girschikofsky, Mundipharma; Alois Lang, Celgene; Hubert
Angermann, Unidata Geodesign GmbH; Reinhard Stauder, Celgene;
Alexander Egle, Celgene; Richard Greil, Bristol-Myers-Squibb, Cephalon,
Celgene;
Honoraria: Lisa Pleyer, Celgene, Bristol-Myers Squibb, Novartis, AOP Orphan
Pharmaceuticals; Thomas Melchardt, Mundipharma; Sonja Burgstaller,
Mundipharma, Novartis, AOP Orphan Pharmaceuticals; Michael Pfeilstöcker,
Celgene, Novartis; Michael Girschikofsky, Pfizer, Mundipharma; Reinhard
Stauder, Ratiopharm, Celgene; Richard Greil, Amgen, Eisai, Mundipharma,
Merck, Janssen-Cilag, Genentech, Novartis, Astra-Zeneca, Cephalon,
Boehringer-Ingelheim, Pfizer, Roche, Bristol-Myers Squibb, Sanofi Aventis;
Peter Krippl, Roche, Amgen, Pfizer, Mundipharma, Galxo Smith Klein,
PharmaMar, Astra Zeneca; Alexander Egle, Celgene;
Research funding: Michael Girschikofsky, Pfizer; Reinhard Stauder, Ratiopharm,
Novartis, Celgene; Richard Greil, GSK, Amgen, Genentech, Ratiopharm,
Celgene, Pfizer, Mundipharma, Cephalon; Peter Krippl, Pfizer, Roche;
Alexander Egle, Celgene;
Expert testimony: Peter Krippl, Amgen, Roche, Mundipharma;
Other remuneration: Thomas Melchardt, travel support: Amgen, Sanofi
Aventis, Roche, Celgene, BMS, Janssen-Cilag, Böhringer Ingelheim; Reinhard
Stauder and Martina Mitrovic were supported by Verein Senioren-Krebshilfe;
Authors’ contributions
All authors had access to all the clinical data, and were kept up-to date with
recent results of the registry via oral presentations from LP at regular
intervals. All authors participated in regular critical discussions concerning
the status and direction of the registry as well as the data to be published.
All authors had the opportunity to review the final manuscript prior to
submission. The primary and corresponding authors had final responsibilityfor the decision to submit for publication. Conception and design: LP, RG;
Statistics and online CRF: HA, LP; Collection and assembly of data: LP, RS, SB,
MS, CT, MP, SS, TM, MM, MG, AL, PK, TS, AE, WL, DV, HA, RG; Data analysis
and interpretation: LP, RG; Manuscript writing: LP; Critical revision of the paper:
LP, RG, AE, RS, SB, MS, CT, MP, SS, TM, MM, MG, AL, PK, TS, WL, DV, HA; Final
approval of Manuscript: LP, RS, SB, MS, CT, MP, SS, TM, MM, MG, AL, PK, TS,
AE, WL, DV, HA, RG; Provision of patients: LP, RS, SB, MS, CT, MP, MG, AL, PK,
TS, AE, WL, DV, RG.
Funding sources
The AAR is a Registry of the ‚Arbeitsgemeinschaft Medikamentöse
Tumortherapie’ (AGMT) Study Group which served as the responsible
sponsor and holds the full and exclusive rights on data. Financial support for
the AGMT was received from Celgene. Celgene had no role in study design,
data collection, data analysis, data interpretation, or writing of the
manuscript.
Non-author contributions
Barbara Rosettani, a Celgene Employee, contributed solely as an operational/
confirmational statistician, without influencing the design of the analyses or
the manuscript. Andrew Brittain, a medical writer at Knowledgepoint360
Group (supported by funding from Celgene), was involved solely for the
correct formatting of the figures. He had no influence on planning, writing
or interpreting the manuscript.
Author details
13rd Medical Department with Hematology and Medical Oncology,
Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for
Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus
Medical University Hospital Salzburg, Müllnerhauptstrasse 48, Salzburg 5020,
Austria. 2Internal Medicine V (Hematology and Oncology), Innsbruck Medical
University, Anichstrasse 35, Innsbruck 6020, Austria. 3Department for Internal
Medicine IV, Hospital Wels-Grieskirchen, Grieskirchnerstrasse 42, 4600, Wels,
Austria. 41st Department of Internal Medicine, Center for Oncology and
Hematology, Wilhelminenspital, Montleartstrasse 37, Vienna 1160, Austria.
5Department for Hematology and Oncology, LKH Leoben-Eisenerz,
Radmeisterstrasse 7-9, Eisenerz 8790, Austria. 6IIIrd Medical Department,
Hanusch Hospital, Heinrich-Collin-Strasse 30, Vienna 1140, Austria. 71st
Medical Department with Hematology, Stem cell transplantation,
Hemostatsis and Medical Oncology, Elisabethinen Hospital, Fadingerstrasse 1,
Linz 4010, Austria. 8Internal Medicine, Hospital Feldkirch, Carinagasse 47,
Feldkirch 6800, Austria. 9Department for Internal Medicine, LKH Fuerstenfeld,
Krankenhausgasse 1, Fuerstenfeld 8280, Austria. 105th Medical Department
with Oncology und Palliative Medicine, Hietzing, Wolkersbergenstrasse 1,
Vienna 1130, Austria. 11Department of Hematology, Medical University,
Auenbruggerplatz 1, Graz 8036, Austria. 12Internal Medicine 3, Center for
Hematology and Medical Oncology, General Hospital-Linz GesmbH,
Krankenhausstrasse 9, Linz 4021, Austria. 13UNIDATA GEODESIGN GmbH,
Gaertnergasse 3, Vienna 1030, Austria.
Received: 11 February 2013 Accepted: 22 March 2013
Published: 29 April 2013
References
1. Lowenberg B: Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin
Haematol 2001, 14:65–75.
2. Stone RM: The difficult problem of acute myeloid leukemia in the older
adult. CA Cancer J Clin 2002, 52:363–371.
3. Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW,
et al: Outcome after induction chemotherapy for older patients with
acute myeloid leukemia is not improved with mitoxantrone and
etoposide compared to cytarabine and daunorubicin: a Southwest
Oncology Group study. Blood 2002, 100:3869–3876.
4. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al: Results of
intensive chemotherapy in 998 patients age 65 years or older with acute
myeloid leukemia or high-risk myelodysplastic syndrome: predictive
prognostic models for outcome. Cancer 2006, 106:1090–1098.
5. Menzin J, Lang K, Earle CC, Kerney D, Mallick R: The outcomes and costs of acute
myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597–1603.
6. Deschler B, de Witte T, Mertelsmann R, Lubbert M: Treatment
decision-making for older patients with high-risk myelodysplastic
Pleyer et al. Journal of Hematology & Oncology 2013, 6:32 Page 12 of 13
http://www.jhoonline.org/content/6/1/32syndrome or acute myeloid leukemia: problems and approaches.
Haematologica 2006, 91:1513–1522.
7. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, et al:
Intensive chemotherapy does not benefit most older patients (age 70 years
or older) with acute myeloid leukemia. Blood 2010, 116:4422–4429.
8. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et
al: A comparison of low-dose cytarabine and hydroxyurea with or
without all-trans retinoic acid for acute myeloid leukemia and high-risk
myelodysplastic syndrome in patients not considered fit for intensive
treatment. Cancer 2007, 109:1114–1124.
9. Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, et al: The
addition of the farnesyl transferase inhibitor, tipifarnib, to low dose
cytarabine does not improve outcome for older patients with AML.
Br J Haematol 2012, 158:519–522.
10. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, et al:
A randomized study of clofarabine versus clofarabine plus low-dose
cytarabine as front-line therapy for patients aged 60 years and older
with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood 2008, 112:1638–1645.
11. Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, et al: Cloretazine
(VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age
60 years or older with previously untreated acute myeloid leukemia.
J Clin Oncol 2007, 25:25–31.
12. Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D,
Masszi T, et al: A randomized phase 3 study of tipifarnib compared with
best supportive care, including hydroxyurea, in the treatment of newly
diagnosed acute myeloid leukemia in patients 70 years or older. Blood
2009, 114:1166–1173.
13. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, et al:
Low-dose cytarabine versus intensive chemotherapy in the treatment of
acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990, 8:272–279.
14. Ziogas DC, Voulgarelis M, Zintzaras E: A network meta-analysis of
randomized controlled trials of induction treatments in acute myeloid
leukemia in the elderly. Clin Ther 2011, 33:254–279.
15. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL,
et al: Further analysis of trials with azacitidine in patients with
myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer
and Leukemia Group B. J Clin Oncol 2006, 24:3895–3903.
16. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A,
et al: Efficacy of azacitidine compared with that of conventional care
regimens in the treatment of higher-risk myelodysplastic syndromes: a
randomised, open-label, phase III study. Lancet Oncol 2009, 10:223–232.
17. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing
U, et al: Azacitidine prolongs overall survival compared with
conventional care regimens in elderly patients with low bone marrow
blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562–569.
18. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al:
The importance of diagnostic cytogenetics on outcome in AML: analysis
of 1,612 patients entered into the MRC AML 10 trial. The Medical
Research Council Adult and Children's Leukaemia Working Parties. Blood
1998, 92:2322–2333.
19. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD,
et al: Clinical application and proposal for modification of the International
Working Group (IWG) response criteria in myelodysplasia. Blood 2006,
108:419–425.
20. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al:
Revised recommendations of the International Working Group for
Diagnosis, Standardization of Response Criteria, Treatment Outcomes,
and Reporting Standards for Therapeutic Trials in Acute Myeloid
Leukemia. J Clin Oncol 2003, 21:4642–4649.
21. Al Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, et al:
Azacitidine in patients with acute myeloid leukemia medically unfit for or
resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma
2012, 53:110–117.
22. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, et al: Azacitidine
for the treatment of patients with acute myeloid leukemia: report of 82
patients enrolled in an Italian compassionate program. Cancer 2012,
118:1014–1022.
23. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, et al: Treatment
of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006,
107:1839–1843.24. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, et al:
Treatment of progression of Philadelphia negative myeloproliferative
neoplasms to myelodysplastic syndrome or acute myeloid leukemia by
azacitidine: a report on 54 cases on the behalf of the Groupe
Francophone des Myelodysplasies. Blood 2010: .
25. van der Helm LH, Alhan C, Wijermans PW, van Marwijk KM,
Schaafsma R, Biemond BJ, et al: Platelet doubling after the first
azacitidine cycle is a promising predictor for response in
myelodysplastic syndromes (MDS), chronic myelomonocytic
leukaemia (CMML) and acute myeloid leukaemia (AML) patients in
the Dutch azacitidine compassionate named patient programme.
Br J Haematol 2011, 155:599–606.
26. Gavillet M, Noetzli J, Blum S, Duchosal MA, Spertini O, Lambert JF: Transfusion
independence and survival in patients with acute myeloid leukemia treated
with 5-azacytidine. Haematologica 2012, 97:1929–1931.
27. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, et al:
Hematologic response to three alternative dosing schedules of
azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009,
27:1850–1856.
28. Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, et al: The
addition of arsenic trioxide to low-dose Ara-C in older patients with AML
does not improve outcome. Leukemia 2011, 25:1122–1127.
29. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE:
Attempts to improve treatment outcomes in acute myeloid leukemia
(AML) in older patients: the results of the United Kingdom Medical
Research Council AML11 trial. Blood 2001, 98:1302–1311.
30. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, et
al: Epigenetic therapy is associated with similar survival compared with
intensive chemotherapy in older patients with newly diagnosed acute
myeloid leukemia. Blood 2012, 120:4840–4845.
31. Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, et al:
Single-agent laromustine, a novel alkylating agent, has significant
activity in older patients with previously untreated poor-risk acute
myeloid leukemia. J Clin Oncol 2010, 28:815–821.
32. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G,
Mayer J, et al: Multicenter, randomized, open-label, phase III trial of
decitabine versus patient choice, with physician advice, of either
supportive care or low-dose cytarabine for the treatment of older
patients with newly diagnosed acute myeloid leukemia.
J Clin Oncol 2012, 30:2670–2677.
33. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC,
Odchimar-Reissig R, et al: Randomized controlled trial of azacitidine in patients
with the myelodysplastic syndrome: a study of the cancer and leukemia
group B. J Clin Oncol 2002, 20:2429–2440.
34. Pierdomenico F, Almeida A: Efficacy, tolerability and cost benefit of a
5-Day Azacitidine Regimen. Blood 2011, 118: . Ref Type: Generic.
35. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellstrom-Lindberg E,
Gattermann N, et al: Continued azacitidine therapy beyond time of first
response improves quality of response in patients with higher-risk
myelodysplastic syndromes. Cancer 2011, 117:2697–2702.
36. Ruter B, Wijermans PW, Lubbert M: Superiority of prolonged low-dose
azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment
in high-risk myelodysplasia patients. Cancer 2006, 106:1744–1750.
37. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al:
Incidence of hematologic malignancies in Europe by morphologic
subtype: results of the HAEMACARE project. Blood 2010, 116:3724–3734.
38. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al:
Clinical-cytogenetic associations in 306 patients with therapy-related
myelodysplasia and myeloid leukemia: the University of Chicago series.
Blood 2003, 102:43–52.
39. Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, et al:
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates
with MDS-related cytogenetic abnormalities and a prior history of MDS
or MDS/MPN but has no independent prognostic relevance: a
comparison of 408 cases classified as "AML not otherwise specified"
(AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Blood 2010, 116:2742–2751.
40. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al:
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a
new tool for risk assessment before allogeneic HCT. Blood 2005,
106:2912–2919.
Pleyer et al. Journal of Hematology & Oncology 2013, 6:32 Page 13 of 13
http://www.jhoonline.org/content/6/1/3241. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol 1982, 5:649–655.
42. Swerdlow SH, Harris NL CE (Eds): World Health Organization Classification of
Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. Ref
Type: Generic.
doi:10.1186/1756-8722-6-32
Cite this article as: Pleyer et al.: Azacitidine in patients with WHO-
defined AML – Results of 155 patients from the Austrian Azacitidine
Registry of the AGMT-Study Group. Journal of Hematology & Oncology
2013 6:32.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
